{
  "num_tested_probands": 5,
  "num_positive_het_probands": 0,
  "positive_phenotypes": [
    "early developmental delay",
    "motor weakness",
    "intellectual disability",
    "severe progressive encephalopathy",
    "acute liver failure",
    "mild dysmorphic facial features",
    "slightly dysmorphic",
    "intrauterine growth retardation",
    "severe axial hypotonia",
    "hypertonia",
    "dystonic posturing of arms and legs",
    "thin upper lip",
    "low set ears",
    "broad nasal bridge",
    "hypertelorism of the eyes",
    "ogival palatum",
    "severe delay of cognitive and motor development",
    "metabolic encephalopathy",
    "decreased awareness",
    "optic atrophy",
    "severe generalized amyotrophy",
    "seizures",
    "extra-pyramidal signs",
    "epilepsy",
    "ptosis",
    "hypoglycaemia",
    "valproate induced hepatotoxicity",
    "severe hepatopathy associated with valproate treatment",
    "non-specific, non-progressive encephalopathy"
  ],
  "num_compound_or_double_hets": 5,
  "explanation": {
    "num_tested_probands": "Each section consistently uses singular terms such as 'the proband' or 'the subject,' indicating one proband per section, totaling five probands across all sections.",
    "num_positive_het_probands": "No sections explicitly mention probands who are heterozygous for a pathogenic variant without being compound heterozygous.",
    "positive_phenotypes": "Phenotypes are explicitly mentioned in each section, with some inferred from context, such as 'mild dysmorphic facial features' and 'extra-pyramidal signs.'",
    "num_compound_or_double_hets": "Each section describes compound heterozygosity explicitly, indicating one compound heterozygote per section, totaling five across all sections."
  }
}